Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer-Reference-Cited by-同舟云学术

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

Published:2015-10 Issue:1 Volume:139 Page:10-16
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Aghajanian Carol,Goff Barbara,Nycum Lawrence R.,Wang Yan V.,Husain Amreen,Blank Stephanie V.

Funder

Genentech

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference20 articles.

1. Ten-year relative survival for epithelial ovarian cancer;Baldwin;Obstet. Gynecol.,2012

2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N. Engl. J. Med.,1996

3. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results;Piccart;J. Natl. Cancer Inst.,2000

4. Latest research and treatment of advanced-stage epithelial ovarian cancer;Coleman;Nat. Rev. Clin. Oncol.,2013

Cited by 267 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nature’s Elixir for Cancer Treatment: Targeting Tumor-induced Neovascularization;Current Medicinal Chemistry;2024-10

2. Urine Protein to Creatinine Ratio for the Assessment of Bevacizumab-Associated Proteinuria in Patients with Gynecologic Cancers: A Diagnostic and Quality Improvement Study;Diagnostics;2024-08-24

3. Global publication productivity and research trends on recurrent ovarian cancer: a bibliometric study;Frontiers in Oncology;2024-07-05

4. Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer;Gynecologic Oncology;2024-07

5. Bevacizumab Combination Therapy Versus Standard Chemotherapy for Ovarian Cancer in Shorter and Longer Follow-Up Duration;American Journal of Clinical Oncology;2024-06-21